Sustained Haematological and Cardiac Responses Following Intravenous Ferric Carboxymaltose in Iron-Deficient Heart Failure with Reduced Ejection Fraction: A 12-Month Prospective Observational Study

Introduction

Iron deficiency is a prevalent comorbidity in heart failure with reduced ejection fraction (HFrEF), and significant in causing anaemia, reducing exercise performance, and heart failure pathology. Ferric carboxymaltose (FCM) intravenously administered can restore iron levels and is not dependent on the digestive system. The study aim to analyse the changes in various physiological parameters following the administration of FCM.